China Traditional Chinese Medicine (570.HK) - Short-Term Performance Pressure Is Hard to Avoid

For poor performance of concentrated TCM granule, China TCM's net profit decreased 50%-60% in 2022H1.Future VBP will further drag down profitability, which will struggle to support valuation expansion
296 Views19 Jul 2022 08:54
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Analytics & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
x